Skip to content

Oncostatin M in Ulcerative Colitis Patients

Serum Oncostatin M in Ulcerative Colitis Patients and Its Relation to Severity and Acute Exacerbation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05974332
Enrollment
99
Registered
2023-08-03
Start date
2023-08-01
Completion date
2024-03-01
Last updated
2023-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ulcerative Colitis

Brief summary

Ulcerative colitis (UC) is a refractory disease characterized by symptoms such as diarrhea, bloody stools, and abdominal pain with repeated relapses and remissions.

Detailed description

Evaluation of UC activity is important, and endoscopic evaluations of mucosal inflammation can facilitate subsequent prognostication. On the basis of these considerations, achievement of mucosal healing is important in inflammatory bowel disease (IBD), and evaluation of IBD using endoscopy is extremely important. However, endoscopic examinations are associated with problems such as physical burden to the patient, cost, and risk of complications. Thus, to avoid the need for frequent endoscopy, noninvasive biomarkers that accurately reflect the endoscopic activity of UC have emerged, and fecal calprotectin (FC) and the fecal immunochemical occult blood test (FIT) are being widely used in clinical practice.

Interventions

DIAGNOSTIC_TESTOncostatin M

Test to diagnosis of Ulcerative colitis

Sponsors

Beni-Suef University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All patients aged \>18 years and \<80 years, of both gender who diagnosed to have UC and given the consent for participation in the study

Exclusion criteria

* 1- Any patient with systemic inflammation as Bronchial asthma. 2- History of cancer or tumor. 3- Autoimmune disease such as rheumatoid arthritis and systemic lupus erythematous

Design outcomes

Primary

MeasureTime frameDescription
Identify if oncostatin M is a good marker6 monthsDiagnosis of Ulcerative colitis and follow up

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026